Drugs & TargetsFree FDA grants priority review for Tecentriq + Abraxane for metastatic triple-negative breast cancer November 16, 2018Vol.44 No.43
Drugs & TargetsFree CHMP gives positive opinion for Kisqali combination therapy for all women with HR+/HER2- locally advanced or metastatic breast cancer November 16, 2018Vol.44 No.43
Drugs & TargetsFree FDA accepts novel clinical trial endpoint in approving Erleada for prostate cancer November 16, 2018Vol.44 No.43
Drugs & TargetsFree Using review pilot program, FDA takes two weeks to approve first-line treatment for peripheral T-cell lymphoma November 16, 2018Vol.44 No.43
Clinical RoundupFree Biodesix test predicts response to atezolizumab in lung cancer November 16, 2018Vol.44 No.43
Clinical RoundupFree Cardiovascular toxicities seen early in treatment with immune checkpoint inhibitors November 16, 2018Vol.44 No.43
Clinical RoundupFree Gradalis presents initial data from phase II U.S. trial for Ewing’s sarcoma November 16, 2018Vol.44 No.43
Clinical RoundupFree Keytruda significantly improved OS compared to chemotherapy in PD-L1 advanced esophageal or esophagogastric junction carcinoma November 16, 2018Vol.44 No.43
Clinical RoundupFree Zymeworks announces updated clinical data for novel bispecific antibody, ZW25 November 16, 2018Vol.44 No.43
Clinical RoundupFree Breast screening linked to 60 percent lower risk of breast cancer death in first 10 years November 16, 2018Vol.44 No.43
